Total Funding
1
36
Total FundingPost-IPO Equity raised
Growth Score
0 pts
Heat Score
-16 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
See more interactive data and historical milestones on desktop for the best experience
201200
NeuroDerm is a clinical-stage pharmaceutical company developing next-generation treatments for central nervous system
Acquired by 
Mitsubishi Tanabe Pharma
- Hila Eitan: General Counsel and Chief Compliance Officer
- Kengo Isshiki: Chief Administration Officer
About the Company
NeuroDerm is a clinical-stage pharmaceutical company developing next-generation treatments for central nervous system (CNS) disorders that will make a clinically meaningful difference in patients’ lives. NeuroDerm’s technology enables new routes of administration for existing drugs that overcome their current deficiencies and achieve enhanced
clinical efficacy.
